NCT07678125

Brief Summary

Periodontal disease remains a highly prevalent chronic inflammatory condition affecting the supporting structures of the teeth and is a leading cause of tooth loss worldwide. Contemporary periodontal therapy is structured into sequential phases, with non-surgical periodontal therapy (NSPT) forming the cornerstone of initial management. Following this phase, re-evaluation of periodontal status is critical to determine treatment outcomes and guide further intervention, including surgical therapy if required (1,2). Re-evaluation phase serves multiple purposes: it allows assessment of tissue response to therapy, measurement of reductions in probing pocket depth (PPD), gains in clinical attachment level (CAL), and evaluation of patient compliance with oral hygiene practices. It also aids in identifying residual pockets or persistent inflammation that may necessitate additional treatment (1,3). Despite its clinical importance, the optimal timing of re-evaluation remains inconsistently defined in the literature (1). Generally, current literature utilizes a timing frame from 1-3 months; up to 9 months (3,4). Current clinical guidelines, including those from the European Federation of Periodontology (EFP), generally recommend assessing whether the end points have been achieved; no periodontal pockets ≥ 5mm with bleeding on probing and no pocket ≥ 6mm (5). Emerging evidence suggests that certain clinical improvements, particularly reductions in inflammation and bleeding on probing (BOP), may occur as early as 4 weeks following therapy, raising questions about whether earlier re-evaluation could be clinically beneficial (2,3). Early reassessment may allow for more timely identification of non-responding sites, enabling prompt intervention and potentially improving overall treatment outcomes. Conversely, other studies indicate that full periodontal healing and maturation of tissues may require longer periods, supporting delayed re-evaluation intervals (1,2,3). Furthermore, patient-related factors such as systemic health, smoking status, and baseline disease severity may influence healing dynamics and thus the appropriate timing for reassessment (1). The heterogeneity of these factors highlights the potential need for a more individualized approach to re-evaluation rather than a fixed universal timeframe. Despite these considerations, there is a notable lack of high-quality comparative studies directly evaluating short-term versus conventional re-evaluation intervals following NSPT. Most available studies focus on treatment outcomes rather than the timing of reassessment itself. This creates a significant gap in the literature, particularly regarding whether earlier re-evaluation could enhance clinical decision-making, improve patient outcomes, or optimize resource utilization in clinical practice. In addition, with increasing emphasis on minimally invasive and patient-centered care, there is a growing need to refine periodontal treatment protocols to ensure efficiency without compromising effectiveness. Determining the optimal timing of re-evaluation could contribute to improved treatment planning, reduced disease progression, and enhanced long-term periodontal stability. Therefore, this study aims to address this gap by investigating the effectiveness and clinical implications of shorter re-evaluation intervals following periodontal therapy, compared to conventional timeframes.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
7mo left

Started Jun 2026

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress24%
Jun 2026Feb 2027

Study Start

First participant enrolled

June 1, 2026

Completed
24 days until next milestone

First Submitted

Initial submission to the registry

June 25, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

July 1, 2026

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2027

Last Updated

July 1, 2026

Status Verified

June 1, 2026

Enrollment Period

8 months

First QC Date

June 25, 2026

Last Update Submit

June 25, 2026

Conditions

Keywords

periodontal disease

Outcome Measures

Primary Outcomes (1)

  • clinical attachment level

    baseline, 4 weeks, 10 weeks

Secondary Outcomes (1)

  • probing depth

    baseline, 4 weeks, 10 weeks

Study Arms (2)

Early Re-evaluation Group 4 weeks

EXPERIMENTAL

Test group with periodontal re-evaluation at 4 weeks following non-surgical periodontal therapy.

Procedure: Early follow up

Delayed Re-evaluation Group 10 - 12 weeks

ACTIVE COMPARATOR

Control group with periodontal re-evaluation at 8-10 weeks following non-surgical periodontal therapy

Procedure: Delayed follow up

Interventions

Test group with periodontal re-evaluation at 4 weeks following non-surgical periodontal therapy

Early Re-evaluation Group 4 weeks

Control group with periodontal re-evaluation at 8-10 weeks following non-surgical periodontal therapy

Delayed Re-evaluation Group 10 - 12 weeks

Eligibility Criteria

Age21 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients above 18 yrs
  • Patients that are systemically healthy
  • Patients diagnosed as Stage III or Stage IV Periodontitis
  • Patients willing to participate in the study and provide informed consent.
  • Patients with no recent history of periodontal therapy
  • Presence of ≥20 natural teeth

You may not qualify if:

  • Patients with a history of medical conditions or diseases that may affect healing or periodontal tissues.
  • Patients who are pregnant
  • Patients on Drugs/medication that may affect the periodontal tissue
  • Smokers or tobacco users
  • Patients that cannot complete the 12-week follow-up period

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gulf Medical University

Ajman, Ajman Emirate, 00000, United Arab Emirates

Location

MeSH Terms

Conditions

Periodontal DiseasesPeriodontitis

Condition Hierarchy (Ancestors)

Mouth DiseasesStomatognathic Diseases

Central Study Contacts

Nesma Shemais, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: split mouth design
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 25, 2026

First Posted

July 1, 2026

Study Start

June 1, 2026

Primary Completion (Estimated)

January 15, 2027

Study Completion (Estimated)

February 15, 2027

Last Updated

July 1, 2026

Record last verified: 2026-06

Locations